Search Result

Results for "

FAAH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FAAH (63) Autophagy (20) Bacterial (1) Cannabinoid Receptor (6) Ceramidase (1) COX (3) Endogenous Metabolite (11) Epoxide Hydrolase (2) Fungal (1) Glutathione Peroxidase (1) Histamine Receptor (1) MAGL (16) Mitophagy (1) Nucleoside Antimetabolite/Analog (1) Phospholipase (1) SARS-CoV (1) Small Interfering RNA (siRNA) (4) TRP Channel (4) Virus Protease (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (17) Metabolic Disease (14) Neurological Disease (45)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

FAAH/MAGL-IN-4	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

FAAH-IN-1	FAAH Autophagy	Metabolic Disease
FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

FAAH-IN-8	FAAH	Neurological Disease
FAAH-IN-8 (compound 11) is a competitive inhibitor of FAAH with an IC₅₀ value of 6.7 nM and a K_i value of 5 nM. FAAH-IN-8 has high blood-brain permeability and a significant antioxidant profile with no neurotoxicity .

FAAH inhibitor 2	FAAH	Neurological Disease
FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC₅₀ of 0.153 μM .

FAAH-IN-5	FAAH MAGL	Neurological Disease
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

FAAH-IN-7	FAAH	Inflammation/Immunology
FAAH-IN-7 is a reversible and potent *FAAH* inhibitor with an IC₅₀ value of 8.29 nM. FAAH-IN-7 suppresses oxidative stress in 1321N1 astrocytes and exhibits notable neuroprotective effect in ex vivo neuroinflammation model .

FAAH/MAGL-IN-3	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

FAAH/MAGL-IN-1	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-1 (compound SIH 3) is a potent *FAAH* and MAGL inhibitor with IC₅₀s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain .

FAAH-IN-6	FAAH	Neurological Disease
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .

FAAH/MAGL-IN-2	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier *FAAH* and MAGL inhibitor with IC₅₀s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment .

FAAH/TRPV1 blocker-1	FAAH TRP Channel	Inflammation/Immunology
FAAH/TRPV1 blocker-1 (compound 2R) is a dual *FAAH/TRP*V1 blocker, with IC₅₀ of 0.12 and 94.9 μM, respectively. FAAH/TRPV1 blocker-1 plays an important role in analgesic and anti-inflammatory research .

FAAH-IN-2 1 Publications Verification O-Desmorpholinopropyl Gefitinib	FAAH Autophagy	Others
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.

FAAH/cPLA2α-IN-1	FAAH Phospholipase	Neurological Disease Inflammation/Immunology
FAAH/cPLA2α-IN-1 is a dual inhibitor of *FAAH* and cPLA2α with IC₅₀s of 32 and 47 nM, respectively .

FAAH Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FAAH Human Pre-designed siRNA Set A contains three designed siRNAs for FAAH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Faah Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Faah Mouse Pre-designed siRNA Set A contains three designed siRNAs for Faah gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Faah Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Faah Rat Pre-designed siRNA Set A contains three designed siRNAs for Faah gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

FAAH/MAGL-IN-5	FAAH MAGL	Neurological Disease
AM6701 is a potent *FAAH/MAGL* inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

FAAH inhibitor 1 Benzothiazole analog 3	FAAH Autophagy	Cancer
FAAH inhibitor 1 (Benzothiazole analog 3) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 18±8 nM .

FAAH2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FAAH2 Human Pre-designed siRNA Set A contains three designed siRNAs for FAAH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

*CB2R/FAAH* modulator-3**	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and *FAAH* inhibitor. The K_i values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

*CB2R/FAAH* modulator-2**	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-2 (compound 26) is a dual targeting modulator that acts as a CB2R agonist and *FAAH* inhibitor. The K_i values for CB2R/FAAH modulator-2 are 10.8 and 152.9 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 6.2 μM. CB2R/FAAH modulator-2 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

*Dual FAAH/sEH-IN-1*	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and *FAAH* (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

*CB2R/FAAH* modulator-1**	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

JP83	FAAH	Neurological Disease
JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC₅₀ of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments .

JP104	FAAH	Neurological Disease
JP104, a aryl carbamate, is an irreversible *FAAH* inhibitor with a pIC₅₀ of ~8 .

JNJ-1661010 Takeda-25	FAAH	Neurological Disease
JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .

Eicosapentaenoyl serotonin EPA-5-HT	FAAH	Metabolic Disease
Eicosapentaenoyl serotonin (EPA-5-HT) is an N-acyl serotonin, a novel lipid present in the gut. Eicosapentaenoyl serotonin inhibits glucagon-like peptide-1 secretion and *FAAH* activity .

PDP-EA	Others	Others
PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .

URB-597 4 Publications Verification KDS-4103	FAAH Autophagy Mitophagy	Neurological Disease
URB-597 (KDS-4103) is an orally bioavailable and selective *FAAH* inhibitor. URB-597 inhibits FAAH activity with an IC₅₀s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .

AA38-3	MAGL FAAH	Metabolic Disease
AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

TC-F2	FAAH	Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

SSR411298	FAAH	Neurological Disease
SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .

PF-3845 1 Publications Verification	FAAH Autophagy	Inflammation/Immunology Cancer
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a K_i of 0.23 µM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .

Biochanin A Maximum Cited Publications 7 Publications Verification 4-Methylgenistein; Olmelin	FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

Carpro-AM1	FAAH COX	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Carpro-AM1 is a dual-acting *FAAH*/substrate-selective COX inhibitor with an IC₅₀ value of 94 nM for FAAH .

WWL154	FAAH	Others
WWL154, an analog of JZL184 that maintains the SH-reactive p-nitrophenyl carbamate group, is a *FAAH-4* inhibitor .

Biochanin A (Standard) 4-Methylgenistein(Standard); Olmelin (Standard)	FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

CAY10435	FAAH	Infection
CAY10435 is a β-ketooxazapyridine, selective *FAAH* inhibitor with antimicrobial activity. CAY10435 binds non-competitively to the FAAH of Dictyostelium discoideum with a Kd value of 0.57 nM .

URB694	FAAH	Cardiovascular Disease Neurological Disease
URB694 is a carbamate *FAAH* inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare ¹¹C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .

URB937	FAAH	Neurological Disease Inflammation/Immunology
URB937 is an orally active and peripherally restricted *FAAH* inhibitor (IC₅₀=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .

Arachidonoyl p-nitroaniline	Others	Others
Arachidonoyl p-nitroaniline is a substrate for the hydrolysis of p-nitroaniline by FAAH in Dictyostelium discoideum with long-chain unsaturated fatty acids. Arachidonoyl p-nitroaniline can be used in enzyme kinetic studies. Examples include determining the hydrolysis rate of Arachidonoyl p-nitroaniline and analyzing the fatty acid amide hydrolase activity of recombinant His-FAAH purified from Dictyostelium to characterize the binding and catalytic specificity of mammalian FAAH enzymes .

Carprofen 2 Publications Verification
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target *FAAH/COX* inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

SA72	FAAH Autophagy	Neurological Disease
SA72 is a highly selective fatty acid amide hydrolase (FAAH) inhibitor.

SA 47	FAAH Autophagy	Metabolic Disease
SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate .

JNJ-40355003	FAAH	Metabolic Disease
JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor .

Carprofen-d3	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library

650 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L013

Neuronal Signaling Compound Library

2542 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.	Compare	Product Name	Species	Source

HY-P702276

	FAAH2 Protein, Human (Cell-Free, His) Fatty-acid amide hydrolase 2; Amidase domain-containing protein; Anandamide amidohydrolase 2; Oleamide hydrolase 2	Human	E. coli Cell-free
	FAAH2 proteins play a central role in cellular processes by catalyzing the hydrolysis of endogenous amidated lipids, including the sleep-inducing lipid oleamide ((9Z)-octadecylamide) and the endocannabinoid anandamide (N-(5Z) , 8Z, 11Z, 14Z-eicosate tetraenoyl)))-ethanolamine) and other fatty amides. FAAH2 Protein, Human (Cell-Free, His) is the recombinant human-derived FAAH2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of FAAH2 Protein, Human (Cell-Free, His) is 532 a.a., with molecular weight of 59.8 kDa.

Cat. No.	Product Name	Application	Reactivity

HY-P82319

FAAH1 Antibody (YA2064)

FA2H; FAAH; FAAH-1; Oleamide hydrolase 1; Oleamide hydrolase
WB, IHC-P Human, Mouse

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks